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Lp(a) (lipoprotein(a)) is a major genetically determined cardiovascular risk factor. High Lp(a) plasma concentra-
tions are associated with coronary heart disease, myocardial 
infarction, aortic valve calcification and stenosis, carotid ath-
erosclerosis, stroke, and venous thromboembolism.1,2 Lp(a) 
concentrations are controlled mostly genetically by the LPA 
locus, which encodes apo(a) (apolipoprotein(a)) as the pri-
mary structural protein of Lp(a) and explains 70% to 90% of 
the Lp(a) concentrations.1
The LPA gene consists of 10 different KIV (kringle IV) 
domains (KIV-1 to KIV-10), 1 KV domain (kringle V), and an 
inactive protease domain.3 The KIV-2 domain is encoded by 
a 5.6-kb large, coding copy number variation, which is pres-
ent in 1 to >40 repeats3 and thus generates >40 isoforms in 
the population.3 The KIV-2 number is inversely correlated to 
the Lp(a) plasma concentration and explains 30% to 70% of 
the concentrations.1 Low-molecular-weight (LMW) isoforms 
(≤22 KIV repeats) are associated with ≈4- to 5-fold higher 
concentrations than high-molecular-weight (HMW) isoforms 
(>22 KIV).1 The smaller allele thus determines the LMW/
HMW group assignment.4 Although >95% of the popula-
tion is heterozygous on DNA, only 30% to 70% present both 
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Objective—Lp(a) (lipoprotein(a)) concentrations are widely genetically determined by the LPA isoforms and show 5-fold 
interpopulation differences. Two- to 3-fold differences have been reported even within Europe. Finns represent a 
distinctive population isolate within Europe and have been repeatedly reported to present lower Lp(a) concentrations 
than Central Europeans. The significance of this finding was unclear for a long time because of the difficult comparability 
of Lp(a) assays. Recently, a large standardized study in >50 000 individuals from 7 European populations confirmed this 
observation but could not provide insights into the causes.
Approach and Results—We investigated Lp(a) concentrations, LPA isoforms, and genotypes of established genetic variants 
affecting Lp(a) concentrations (LPA variants, APOE isoforms, and PCSK9 R46L) in the Finnish YFS (Cardiovascular 
Risk in Young Finns Study) population (n=2281) and 3 Non-Finnish Central European populations (n=10 003). We 
observed ≈50% lower Lp(a) concentrations in Finns. The isoform distribution was shifted toward longer isoforms, and 
the percentage of low-molecular-weight isoform carriers was reduced. Most interestingly, however, Lp(a) was reduced in 
each single-isoform group. In contrast to the known inverse relationship between LPA isoforms and Lp(a) concentrations, 
especially very short isoforms presented unexpectedly low Lp(a) concentrations in Finns. The investigated genetic 
variants, as well as age, sex, and renal function, explained 71.8% of the observed population differences.
Conclusions—The population differences in Lp(a) concentrations between Finnish and Central European populations originate not 
only from a different LPA isoform distribution but suggest the existence of novel functional variation in the small-isoform range.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
1230-1241. DOI: 10.1161/ATVBAHA.118.310865.)
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isoforms also in plasma.3,5 Null alleles can be caused by large 
alleles, which tend to be nonexpressed or by 3 known loss-of-
function (LOF) mutations.6–8
To date, most studies did not identify Lp(a)-modifying 
genes outside the LPA locus. Only recently, 2 additional 
genes were implicated into Lp(a) metabolism: APOE9–12 and 
PCSK9.13,14 The isoform APOE2 is associated with 15% lower 
Lp(a) concentrations,9,10 whereas the Lp(a)-increasing effect 
of APOE49 is controversial9,15 and vanishes after apo(a) iso-
form adjustment.10 In line with the effects of PCSK9 inhibi-
tors,16 the PCSK9 LOF mutation R46L (rs11591147) with 
a minor allele frequency (MAF) of 3% was associated with 
≈10% lower Lp(a) concentrations in a Danish population.13
Lp(a) concentrations show pronounced interethnical differ-
ences. In whites, Malay, Chinese, and Inuit, the distribution of 
Lp(a) concentration is extremely right skewed17 (median Lp(a), 
≈10–12 mg/dL), whereas Africans present a rather Gaussian-like 
distribution and 2- to 3-fold higher Lp(a) levels than whites.3,5,17 
Indians present intermediary concentrations.17 However, lacking 
standardization of Lp(a) quantification18 and the difficult con-
version between mass-based (mg/dL) and molar-based (nmol/L) 
quantification18 hampers precise interpopulation comparisons.
The distribution and impact of the apo(a) isoforms differ 
between ethnicities.3,5 The isoform explains 28% of the Lp(a) 
concentration in Sudanese but 70% in Chinese.19 Chinese have 
a low number of null alleles, whereas Germans, Ghanaians, 
and San have more 1-isoform carriers, which tend to show 
lower Lp(a) concentrations than 2-isoform carriers.20 In 
whites, the nonexpressed isoform is mostly the larger allele, 
whereas in blacks, the distribution of nonexpressed alleles is 
more U shaped, with an increased proportion of nonexpressed 
isoforms occurring both among very short and very long iso-
forms.5 Accordingly, differences in the frequency of some 
Lp(a) concentration-modifying sequence variations (SNPs 
[single nucleotide polymorphisms] and STRs [short tandem 
repeats]) have been shown between populations.3,5
Within Europeans, Finns represent a genetically dis-
tinct population isolate.21,22 Lp(a) concentrations have been 
reported to be lower in Finns than in Central European popu-
lations,7,23–27 but the significance of this finding was unclear 
because of the lacking standardization in Lp(a) quantification 
and small sample numbers in early studies. Only recently, this 
was confirmed by Waldeyer et al28 in a standardized study of 
7 European cohorts (n=56 804). The authors confirmed a clear 
reduction of Lp(a) in Finns and assumed a potential difference 
in isoform distributions as possible cause.
Indeed, several putative Lp(a)-regulating SNPs present 
marked differences in MAF in Finns compared with Non-
Finnish Central Europeans (NFE). The donor splice-site muta-
tion rs41272114,7 which is associated with an Lp(a) reduction 
by 5.25 mg/dL,7 is more frequent in Finns (MAF=0.0635) than 
in Tyroleans (MAF=0.053)7 or in British (PROCARDIS study 
[Precocious Coronary Artery Disease Study], MAF=0.0329; 
UK Biobank, MAF=0.02).30 Also, a second rare splice-site 
variant (rs143431368)6 shows frequency differences between 
Finns and NFEs (MAF, ≈0.03 in Finns versus 0.003 in NFE) 
as reported by the Exome Aggregation Consortium (ExAC)31 
and UK Biobank.30 Finally, also differences in the allele fre-
quencies for PCSK9 R46L and APOE2 have been reported 
in Finns. Both are associated with reduced Lp(a),9,10,13 but, 
although APOE2 frequency is reduced in Finns by ≈5032 and 
does, therefore, not contribute to the lower Lp(a) concentra-
tions, the PCSK9 R46L LOF variant is reported to be markedly 
more frequent (MAF=0.179 versus 0.035 in the ExAC data31).
To investigate the factors contributing to the population 
differences in Lp(a) concentrations, we report here a com-
prehensive investigation in a Finnish (n=2281) and 3 large 
Central European studies (n
total
=10 003). By combining SNP 
and isoform data for all samples, we assess (1) the distribu-
tion of isoforms in Finns compared with NFE and (2) dissect 
the relative contribution of isoforms and established Lp(a)-
regulating SNPs to the low Lp(a) levels observed in Finns. 
Most importantly, all measurements of Lp(a) concentrations 
and apo(a) isoforms have been done centrally in 1 laboratory 
to keep methodological influences low.
Materials and Methods
Populations
Details on the study populations are reported in Table 1. The CoLaus33 
study (Cohorte Lausannoise) is a single-center, prospective study, 
including 6182 randomly selected white subjects aged 35 to 75 years 
from the city of Lausanne in Switzerland. Only individuals with 4 
grandparents of European origin were included in the genetic study. 
The major aims of the CoLaus study are the investigation of prevalence 
and determinants of cardiovascular disease and cardiovascular risk 
factors in the Lausanne population. The analysis data set comprised 
of 3998 participants with all genotypes and Lp(a) values available.
The KORA cohorts (Cooperative Health Research in the Region 
of Augsburg, Kooperative Gesundheitsforschung in der Region 
Augsburg) are several population-based cohorts representative of 
the general population in Augsburg, Germany, and 2 surrounding 
counties. Ten-year age–sex strata have been sampled from the 25- to 
74-year-old population with a stratum size of 640 subjects. The KORA 
F334 study was conducted in the years 2004/2005 as a follow-up study 
of the KORA S3 survey (1994/1995). The KORA F434 study was con-
ducted in the years 2006/2008 and is a follow-up study of the KORA 
S4 survey (1999/2001). Both studies contain an independent nonover-
lapping sample drawn from the same study region. The analyses data 
set comprised of 3089 participants in KORA F3 and 2916 participants 
in KORA F4, from which genotypes and Lp(a) values were available.
The YFS (Cardiovascular Risk in Young Finns Study)35 is a pro-
spective multicenter study from Finland initiated in 1980 (baseline 
Nonstandard Abbreviations and Acronyms
apo(a) apolipoprotein(a)
eGFR estimated glomerular filtration rate
HMW high molecular weight
KIV kringle IV
KORA Cooperative Health Research in the Region of Augsburg, 
Kooperative Gesundheitsforschung in der Region Augsburg
KV  kringle V
LMW low-molecular weight
LOF loss of function
Lp(a) lipoprotein(a)
LPA apolipoprotein(a) gene
MAF minor allele frequency
NFE Non-Finnish Central European
SISu Sequencing Initiative in Suomi
YFS Cardiovascular Risk in Young Finns Study
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age, 3–18 years). Children (4320) aged 3, 6, 9, 12, 15, and 18 years 
were randomly chosen from the population register from the 5 
Finnish university cities with medical schools (Helsinki, Kuopio, 
Oulu, Tampere, and Turku). Several follow-ups during 30 years to 
investigate childhood risk factors for cardiometabolic outcomes have 
been performed. Lp(a) phenotype information was available for 2281 
participants. The measurements included in this work have been 
done on materials from the follow-up in the year 2001, where 2283 
Table 1. Descriptive Statistics Continuous Variables Shown as Mean±SD and Percentiles (25%/50%/75%)
 YFS (n=2281)* NFE (n=10 003)* CoLaus (n=3998)* KORA F3 (n=3089)* KORA F4 (n=2916)*










Women, n (%) 1255 (55.0%) 5230 (52.3%) 2141 (53.6%) 1584 (51.3%) 1505 (51.6%)






























LMW isoform carriers, n (%) 361 (15.8%) 2272 (22.7%) 846 (21.2%) 707 (22.9%) 719 (24.7%)


















































Triglycerides, mg/dL§ 119±76 (71/97/142) 135±100 (77/109/162) 120±78 (71/97/142) 165±126 (88/135/201) 125±89 (72/105/151)
Type-2 diabetes mellitus, n (%) 78/2266 (3.4%) 912/9994 (9.1%) 436/3996 (10.9%) 240/3082 (7.8%) 236/2916 (8.1%)










SNP MAF/APOE haplotype frequency
  rs143431368 (LPA) 0.027 0.002 0.002 0.002 0.002
  rs41272114 (LPA) 0.049 0.031 0.034 0.029 0.028
  rs3798220 (LPA) 0.012 0.015 0.015 0.016 0.014
  rs10455872 (LPA) 0.029 0.056 0.056 0.053 0.060
  rs11591147 (PCSK9) 0.039 0.013 0.010 0.015 0.016
  rs7412 (APOE) 0.043 0.068 0.052 0.084 0.073
  rs429358 (APOE) 0.195 0.131 0.128 0.136 0.132
  APOE2/E2 0.001 0.003 0.001 0.006 0.004
  APOE2/E3 0.062 0.111 0.089 0.130 0.121
  APOE2/E4 0.020 0.018 0.013 0.026 0.016
  APOE3/E3 0.580 0.640 0.669 0.611 0.632
  APOE3/E4 0.302 0.210 0.213 0.209 0.207
  APOE4/E4 0.034 0.017 0.015 0.018 0.020
eGFR indicates estimated glomerular filtration rate; HDL, high-density lipoprotein; HMW, high molecular weight; KIV, kringle IV; KORA, Cooperative Health Research 
in the Region of Augsburg, Kooperative Gesundheitsforschung in der Region Augsburg; LDL, low-density lipoproteins; LDL-C, low-density lipoprotein cholesterol; 
LMW, low-molecular weight; Lp(a), lipoprotein(a); MAF, minor allele frequency; NFE, Non-Finnish Central European; SNP, single nucleotide polymorphisms; and YFS, 
Cardiovascular Risk in Young Finns Study.
*Based on samples with available Lp(a) concentration.
†Shorter isoform present.
‡LDL cholesterol levels corrected for Lp(a) concentrations.55
§KORA F3 participants were nonfasting.
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individuals (63.5% of the original cohort) participated in clinical 
examinations, and 2620 (72.9%) returned questionnaires.
Informed consent was obtained from each participant, and the 
studies were approved by the respective institutional review boards.
Lp(a) Quantification Using ELISA
Lp(a) plasma concentrations were measured using a sandwich ELISA 
method described by Kronenberg et al36 with minor modifications. All 
measurements were done in the same laboratory (Division of Genetic 
Epidemiology, Medical University of Innsbruck, Austria).
In brief, the ELISA plates (Nunc-Immuno MicroWell Maxi Sorp 
flat bottom design, MaxiSorp surface treatment; Thermo Fisher 
Scientific, Waltham) were coated using an affinity-purified poly-
clonal rabbit anti-human apo(a) antibody in a final concentration of 5 
µg/mL in 1× PBS containing 1 mg/mL NaN
3
. The plates were incu-
bated with 100 µL antibody dilution (3 hours, 37°C), washed 3× (1× 
PBS+0.05% v/v Tween-20), and blocked with 200-µL 0.1% wt/vol 
casein in 1× PBS pH 7.3 (30 minutes, 37°C). To ensure measuring 
each sample within the linear range of optical density, all samples 
were diluted into the ELISA plate twice (1:150 and 1:1500 in Assay 
Buffer [Microcoat, Bernried, DE] of 1:30 and 1:1000 predilutions in 
1× PBS, pH 7.3). A 7-point standard curve ranging from 0.32 mg/dL 
to 5 µg/dL was created (with an additional blank representing the zero 
point). Duplicate determinations of 4 reference samples were used as 
longitudinal interassay controls.
The coated plates were incubated with the analyte for 1 hour at 
37°C. Detection was performed using a horseradish peroxidase-con-
jugated monoclonal antibody (1A2; in 0.1% wt/vol casein, 1× PBS, 
pH 7.3) directed against the KIV domain37 and not cross-reacting with 
plasminogen (1 hour, 37°C). After 3 washing steps as described above, 
100 µL Blue Star TMB substrate (Adaltis, Guidonia Montecelio, IT) 
was added (30 minutes, room temperature). Reaction was stopped by 
adding 50 µL 0.5 mol/L sulfuric acid. Measurement of the absorption 
(dual wavelength, analyte: 450 nm, reference: 690 nm) was done using 
a Microplate Reader (BioRad Benchmark Plus; Bio-Rad Laboratories, 
Hercules), and concentrations were calculated based on the standard 
curve (expressed as mg/dL). All dilution and pipetting steps were done 
using liquid handling robotics (Tecan, Männedorf, CH).
apo(a) Isoform Determination by Western Blot
apo(a) isoform determination has been done as previously described 
in Kronenberg et al38 with minor modifications. All measurements 
were done in the same laboratory (Division of Genetic Epidemiology, 
Medical University of Innsbruck, Austria) and evaluated by the same 
experienced scientist.
In brief, Lp(a) concentrations of each sample were determined 
by ELISA as described above, and all plasma samples were then 
diluted with PBS to a standardized Lp(a) concentration of 30 ng/µL. 
Ten microliters of this dilution were mixed with 20 µL of reduc-
ing sample buffer (15.38% v/v glycerol, 7.69% 2-mercaptoethanol, 
3.85% v/v SDS, 0.177% v/v 4-ethylmorpholine, and 0.077% wt/vol 
bromophenol blue) resulting in an Lp(a) concentration of 10 ng/µL. 
Protein was denatured at 98°C for 5 minutes. Subsequently, 150 ng 
(15 µL of the 10-ng/µL solution) were applied on a 1.46% agarose gel 
supplied with 0.08% SDS and separated for 18 hours (0.04 A, con-
stant current). Samples with an Lp(a) concentration <15 ng/µL (ie, 
1.5 mg/dL) were not diluted with PBS, but a higher volume of sample 
was applied on the gel to obtain an equal apo(a) mass. A size stan-
dard consisting of a mixture of 5 plasma samples expressing only 1 
apo(a) isoform each (13, 19, 23, 27, and 35 KIV repeats, determined 
by pulsed-field gel electrophoresis39) was applied every seventh sam-
ple on the gel to detect uneven gel running and minimize distance 
between samples and standards. After electrophoresis, the proteins 
were transferred to a polyvinylidenfluorid membrane (Immobilion-P; 
Millipore, Darmstadt, DE) using semidry blotting (Perfect Blue 
Semi Dry Blotter; VWR, Vienna, Austria). The membrane was first 
equilibrated in methanol for 30 seconds, and then rinsed in water 
and afterward equilibrated in blotting buffer (20% v/v ethanol, 16 
mmol/L Tris, and 120 mmol/L glycine). The transfer was done for 
45 minutes and 250 mA having the blotting stack semidry in Blotting 
Buffer. The membrane was then blocked for at least 30 minutes at 
37°C using buffer C (85 mmol/L NaCl, 10 mmol/L Tris, 0.2% Triton 
X-100, and 1% BSA) and incubated in the first antibody (1A237 in a 
concentration of 168 ng/mL in buffer C) for 2 hours at room tempera-
ture on a shaker. After 3 wash steps in TTBS (Tris-buffered saline 
buffer with Tween-20; 20 mmol/L Tris-HCl pH 7.4, 0.5 mol/L NaCl, 
and 0.05% Tween-20) of 15 minutes each, the membrane was incu-
bated with horseradish peroxidase-conjugated goat anti-mouse anti-
body (401253, Millipore, Darmstadt, DE; diluted 1:13 333 in buffer 
C) for 45 minutes on a shaker at room temperature. Residual sec-
ondary antibodies were removed by 3 washing steps (15 minutes in 
TTBS each); enhanced chemiluminescence substrate (WesternBright 
Chemiluminescenzce Spray; Biozym, Hessisch Oldendorf, DE) was 
added, and the signals were detected on an Amersham Hyperfilm for 
enhanced chemiluminescence (GE Healthcare, Vienna, Austria).
Genotyping
1000 Genomes40-imputed genome-wide genotyping data were avail-
able for CoLaus and YFS, whereas genotypes imputed using the 
haplotype reference consortium41 panel were available for KORA F3 
and KORA F4. These data were used for evaluation of LPA SNPs 
rs3798220, rs10455872, rs143431368, and rs41272114, as well as 
PCSK9 rs11591147 (PSCK9 R46L) and the APOE isoforms E2, 
E3, and E4 (rs7412 and rs429358). APOE haplotypes are defined 
as follows: APOE2/E2: rs7412=TT and rs429358=TT, APOE2/
E3: rs7412=CT and rs429358=TT; APOE2/E4: rs7412=CT and 
rs429358=CT, APOE3/E3: rs7412=CC and rs429358=TT; APOE3/
E4: rs7412=CC and rs429358=CT, APOE4/E4: rs7412=CC and 
rs429358=CC. Imputation quality is given in Table VII in the online-
only Data Supplement and in Mack et al 2017.10
Statistical Methods
In samples heterozygous for apo(a) isoforms, the smaller of the 2 
isoforms present is commonly used for assignment to the LMW (≤22 
KIV) or the HMW (>22 KIV) groups.4 Because genotyping using 
pulsed-field gel electrophoresis is not feasible on population scale, we 
refer to the Western blot result throughout the article, when assign-
ing zygosity. For statistical analysis and data presentation of hetero-
zygous samples, the smaller isoform present was termed isoform 1, 
independent of its size, and the larger isoform was named isoform 2. 
Accordingly, all isoform-based adjustments and stratifications were 
done based on the smaller isoform (unless otherwise stated).
Because of the skewed distribution of the Lp(a) trait, nonparamet-
ric tests were used to compare median values of Lp(a) between the 
studies (Mann–Whitney–Wilcoxon test). Dunn post hoc test for mul-
tiple comparisons was used to test for significant median differences 
between all possible pairwise tests between studies. Proportions were 
tested by χ2 test. In regression and mediation models, inverse-normal 
transformation was used for Lp(a) to adhere to the normal distribution 
assumption for statistical tests. Equal distribution of isoforms within 
carriers of rs10455872 and rs3798220 in YFS and NFE was tested 
using the Kolmogorov–Smirnov test.
We used a multivariable regression model to evaluate the joint influ-
ence of the SNPs rs10455872, rs3798220, rs143411368, rs41272114, 
and rs11591147, APOE2 and APOE4-carriers, the isoforms (isoform 
1), age, sex, and estimated glomerular filtration rate (eGFR) on Lp(a). 
Imputed genotype scores were used on a continuous scale, which cor-
responds to an additive coding. The eGFR was included to account 
for renal function, which is one of the few established nongenetic 
modifiers of Lp(a) concentrations.42,43 eGFR was calculated according 
to Levey et al,44 (CDK EPI [Chronic Kidney Disease Epidemiology 
Collaboration] creatinine equation). For the isoforms, a nonlinear 
spline was used. The multivariable regression models were performed 
in each of the 4 populations individually and for all Non-Finnish 
European studies combined (NFE) using a mixed model accounting 
for the study as a random effect (package mgcv in R).
To investigate whether the lower Lp(a) values in Finns can 
be explained by the evaluated variables, we performed a formal 
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mediation analysis. This means that the effect on Lp(a) of being 
Finnish is decomposed into the effect portions, which are medi-
ated by the isoforms, by the SNPs, and by other factors, which 
differ between YFS and the Non-Finnish European studies (see the 
Results section). Because the participants in the YFS are younger 
than the participants in the other Non-Finnish studies, age and, in 
consequence, better kidney function could also possibly explain 
the difference in Lp(a) distribution. Therefore, eGFR and age 
were also included as potential mediating variables. Technically, 
a binary variable (Finnish versus Non-Finnish) was created and 
regressed onto inverse-normal transformed Lp(a) values. This 
effect is denoted as the total effect. Then, this simple regression 
model was adjusted for the potential mediating variables (age, sex, 
eGFR, isoform 1, and the investigated SNPs). The percentage by 
which the total effect is attenuated is the relative mediated effect, 
which can be decomposed into their single parts (indirect effects, 
herein after referred to as explained effects). The remaining effect 
is the direct effect of the variable being Finnish. This is actually 
the remainder, which cannot be explained by the included vari-
ables (herein after referred to as unexplained effects). Assumptions 
of the mediation model are (1) association of the mediators with 
the outcome (this was set to a P value <0.1) and (2) association 
of the exposure (the Finnish versus Non-Finnish effect) with the 
outcome (P value, <0.1). Only those variables were included in 
the mediation analysis that fulfilled these assumptions. Model 
assumptions, decomposition into single indirect effects (time of 
resampling, n=100), and bootstrap confidence intervals (number 
of times of bootstrap resampling, n=500) were performed using 
the package mma in R. All statistical analyses were done with R 
(http://www.r-project.org).
Results
YFS Present Reduced Lp(a) Concentrations 
Compared With Central Europeans
We determined Lp(a) concentrations and apo(a) isoforms 
in the YFS (n=2281) and in the 3 Central European popu-
lation CoLaus (n=3998), KORA F3 (n=3089), and KORA 
F4 (n=2916). All measurements were performed in the 
same laboratory using standardized ELISA and Western 
blot assays. Median Lp(a) concentrations were similar 
in all Central European populations (P>0.59 for all pair-
wise comparisons between Central European populations) 
but significantly different between YFS and all Central 
European studies (Figure 1A; Table I in the online-only 
Data Supplement; all P ≤1.38×10−58 for all pairwise com-
parisons using Dunn post hoc test). Therefore, for all sub-
sequent analyses, CoLaus, KORA F3, and KORA F4 were 
combined to the Non-Finnish Europeans (NFE) population. 
The median Lp(a) concentration in YFS was significantly 
lower than in NFE (6.3 versus 11.6 mg/dL; P=8.15×10−91; 
Figure 1A). This difference was present both in men and 
women and when restricting the analysis only to the age 
range ≥32 to ≤39 years allowing a similar age distribution 
of all studies (Table I in the online-only Data Supplement). 
When stratifying Lp(a) concentrations into 5-mg/dL strata, 
concentrations of 0 to 5 mg/dL were overrepresented in YFS 
compared with NFE (42.3% versus 24.7%; P=5.22×10−64; 
Figure 1B). Accordingly, less individuals showed concen-
trations >30 mg/dL and >50 mg/dL, which are commonly 
deemed as thresholds for increased cardiovascular risk45,46 
(>30 mg/dL, 12.1% versus 25.3%; >50 mg/dL, 3.9% ver-
sus 14.1%; P=2.32×10−41 and P=1.17×10−41; Figure III in the 
online-only Data Supplement).
Differences in Isoform Distributions 
Between YFS and NFE
The Lp(a) concentration is highly dependent on the number 
of KIV repeats. We, therefore, investigated whether the apo(a) 
isoform distribution is shifted toward larger isoforms in YFS 
compared with NFE, which could potentially explain the 
lower Lp(a) levels observed in YFS.
Isoforms ≤25 KIV repeats were more frequent in NFE 
than in YFS, whereas YFS presented higher frequencies of 
isoforms with >28 KIV domains (Figure 2A). Accordingly, 
LMW frequency was significantly reduced in YFS com-
pared with the NFE populations (361/2282 [15.8%] versus 
2272/10 003 [22.7%]; P=5.83×10−13; Figure 2B). The median 
size of the smaller isoform (isoform 1) was larger in YFS than 
in NFE (29 versus 27 KIV repeats; P=8.21×10−37; Figure 2C; 
Table II in the online-only Data Supplement). In heterozygous 
individuals, the differences in the distribution of the larger iso-
form (isoform 2) were less pronounced but still significant (36 
versus 35 KIV repeats; P=3.54×10−12; Figure 2D; Table II in 
the online-only Data Supplement).
Interestingly, the Lp(a) concentrations were lower in 
YFS than in NFE even within the LMW and HMW groups 
(Figure 3A). Because this could arise from a shift of the iso-
form distribution toward higher isoforms within the groups 
(thus reducing the group mean without changing group assign-
ment), we stratified the Lp(a) isoforms into more granular sub-
groups as done in earlier studies.47 YFS showed reduced Lp(a) 
concentrations in all subgroups (Figure 3B; Table IV in the 
online-only Data Supplement). Also, the percentage of homo-
zygous null allele carriers (ie, samples that do not present any 
of the 2 LPA isoforms in plasma as detectable by Western 
blotting) was higher in YFS than in NFE (n=36 [1.6%] versus 
n=70 [0.7%]; P=7.25×10−5). However, the median Lp(a) con-
centration of the entire YFS cohort increased only marginally 
from 6.32 to 6.46 mg/dL after exclusion of the homozygous 
null allele carriers.
Frequency of Established Lp(a)-Regulating SNPs
The APOE isoforms and PCSK9 R46L have been recently 
established as novel genetic regulators of Lp(a).9,10,13 As 
described in detail in the Introduction section, both genetic 
variants show differences in allele frequencies between 
Finns and Central Europeans. The same applies to 2 well-
known LPA splice-site variants6,7 (Table 1). We, therefore, 
evaluated to which extent these variants contribute to the 
differences in Lp(a) concentrations between YFS and NFE. 
YFS presented a higher frequency of E3/E4 and E4/E4 
(P=3.72×10−20 and P=1.04×10−6, respectively) and lower 
frequencies of E2/E3 (P=1.41×10−11; Table 1). Conversely, 
rs11591147, rs143431368, and rs41272114 were more 
frequent in YFS than in NFE (Table 1; P=4.79×10−29, 
P=6.77×10−83, and P=1.44×10−8, respectively). They repre-
sent, therefore, valid putative determinants for the observed 
differences in Lp(a).
Moreover, the LPA variants rs379822048 and rs1045587248, 
which have been reported to tag small isoforms (19–21 and 17–
20 KIV repeats, respectively),48 were included. Both showed 
the same isoform distribution in YFS as in NFE (P=0.61 and 
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P=0.20; Figure VII in the online-only Data Supplement). The 
rs10455872 frequency was ≈50% lower in YFS (which is also 
in line with the lower frequency of short isoforms), whereas 
no pronounced frequency difference was observed for the 
rarer rs3798220 variant.
Association of Potential Mediating 
Factors With Lp(a) Concentrations
We investigated LPA isoform distribution, LPA and PCSK9 
LOF frequencies, and APOE isoform frequencies, as well 
as sex, age, and renal function, estimated by eGFR1,5 as 
potential mediators of the observed population differences. 
Results from multiple regression models for each factor on 
Lp(a) are reported in Table 2 (YFS and NFE) and Table V 
in the online-only Data Supplement (single studies). Among 
the genetic factors, isoforms were highly associated with 
Lp(a) in a nonlinear fashion (Figure 4), whereas APOE2 and 
the SNPs rs143411368 and rs41272114, which are more 
frequent in the YFS, showed an Lp(a)-decreasing effect. 
Conversely, rs10455872 and rs378220 were associated with 
increased Lp(a), but only rs10455872 shows a pronounced 
frequency difference between YFS and NFE and thus poten-
tially contributes to the Lp(a) difference. No association 
was observed for PCSK9 R46L (rs11591147) and APOE4 
Figure 1. Distribution of Lp(a) (lipoprotein(a)) concentrations. A, Median Lp(a) concentrations for each population and the combined Non-
Finnish Europeans (NFE) group. YFS (Cardiovascular Risk in Young Finns Study) shows ≈50% lower Lp(a) concentrations. Because of 
the large variance of Lp(a) concentrations, only medians and 25%/75% percentiles are shown to enhance comprehensibility. Full figure is 
given in Figure I in the online-only Data Supplement. B, Frequencies of Lp(a) concentrations for YFS and NFE stratified by 5 mg/dL strata. 
The 0 to 5 mg/dL group is markedly larger, and the relative frequencies in almost all strata >30 mg/dL are substantially smaller in YFS 
than in NFE. Figure II in the online-only Data Supplement shows nonclustered NFE. KORA, Cooperative Health Research in the Region of 
Augsburg, Kooperative Gesundheitsforschung in der Region Augsburg.
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carrier status, despite their frequency difference between 
YFS and NFE.
The multiple adjusted effect of isoform 1 on Lp(a) is 
shown in Figure 4. In general, Lp(a) decreases with increas-
ing KIV repeats, although not linearly. Because in YFS the 
distribution of isoforms is shifted to higher repeat numbers, 
lower Lp(a) values are expected. Both in YFS and NFE, 
Lp(a) decreases rather sharply at >22 repeats. The nonlinear 
relationship is consistent in all 3 Non-Finnish studies and is 
also consistent for HMW isoforms in YFS. Interestingly, the 
effect of isoform 1 being <20 KIV repeats on Lp(a) concen-
trations differs between YFS and NFE. Although in NFE the 
Lp(a) concentrations still rise for isoforms <20, the Lp(a) 
values decrease in YFS.
Among the study-specific factors, age and female sex 
were associated with increased Lp(a) values, whereas eGFR, 
which is higher in the YFS, was associated with a decreased 
Lp(a) (although not significantly). Because YFS individuals 
are younger and present better renal function than those in 
the NFE studies, Lp(a) values are lower in YFS also in conse-
quence of the age effect.
Mediation Analysis Explaining the Differences in 
Lp(a) Concentrations Between Finns and Non-Finns
The multiple regression model (Table 2) indicates that both 
genetic and environmental factors, which are associated with 
reduced Lp(a) and which are more frequent in YFS than in 
NFE, contribute to lowering Lp(a) in YFS. To identify the 
relative contribution of these factors, we conducted a formal 
mediation analysis. All variables of the multiple regression 
models were included as potential mediators of the “Finns 
effect” on Lp(a), except SNP rs11591147, which was not 
significant in the multiple regression model and thus did not 
fulfill the criteria to be included as a mediator (Table VI in 
the online-only Data Supplement), and rs3798220, which was 
not identified as an independent modifier (Table VII in the 
online-only Data Supplement; column P value 2). Altogether, 
71.8% of the Finns effect is determined by the included medi-
ators, which leaves 28.2% unexplained (Figure 5). The largest 
contributors to reduced Lp(a) concentrations in YFS are the 
isoforms (27.3%), followed by age (26.4%), eGFR (10.4%), 
rs41272114 (4.0%), and rs143411368 (3.8%), whereas 
APOE2 frequency contributed inversely (−1.8%).
Figure 2. apo(a) (apolipoprotein(a)) isoform distribution in YFS (Cardiovascular Risk in Young Finns Study) and Non-Finnish Central 
Europeans (NFE). A, Isoform 1 in YFS and NFE stratified by groups of 3 KIV (kringle IV) repeats (except the group with shortest isoforms 
11–16). YFS shows a higher frequency of carriers >28 KIV repeats, compared with NFE. The number of carriers in each isoform stratum 
is given in Table IV in the online-only Data Supplement. B, Low-molecular-weight (LMW; at least 1 isoform with ≤22 KIV repeats) and 
high-molecular-weight (HMW) carriers (only isoforms with >22 repeats) in YFS and NFE. HMW individuals are more common in YFS. 
P=5.83×10−13. C and D, apo(a) isoform distribution of the 2 alleles. The violin plots show distributions of the smaller allele (isoform 1) and 
the larger allele (isoform 2, if detectable). The isoform distribution in YFS is shifted toward larger alleles. Diamonds, median; black dots, 
25th and 75th percentiles; red dots, 10th and 90th percentiles. For details and unclustered NFE data, see Figure IV in the online-only Data 
Supplement and Table III in the online-only Data Supplement.
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Discussion
Lp(a) concentrations show pronounced interethnic and inter-
population variability.5,17,19 Several reports showed lower 
Lp(a) concentrations in Finns than in other European popu-
lations,23–27,49 but the small sample numbers of early studies 
and the nonstandardized Lp(a) quantification methods ham-
pered a direct comparison. Waldeyer et al28 recently confirmed 
lower median Lp(a) concentrations (≈−58%) in the Finnish 
FINRISK cohort compared with Central European popula-
tions. However, the causes could not be addressed. Various 
causes are conceivable: (1) differences in the isoform distribu-
tion, (2) differences in the frequency of Lp(a)-lowering vari-
ants, or (3) differences in modifier genes.
To dissect the relative contribution of these factors in 
a standardized study, we determined apo(a) isoforms and 
Lp(a) concentrations with the same assays for 10 003 Central 
European whites from 3 population-based studies (NFE) and 
1 Finnish study (YFS; n=2281).10 The contributions of iso-
form distribution, LPA LOF mutations and variants, APOE 
genotypes, and PCSK9 R46L were assessed.
We found that a consistent part of the differences in Lp(a) 
concentrations can be explained by the common action of (1) 
isoform distribution, (2) LPA variants, and (3) APOE geno-
types. Additionally, we observed that in Finns, the Lp(a) con-
centrations were reduced in all apo(a) isoform groups.
The isoform distribution in Finns was shifted toward 
longer isoforms (Figure 2), which accounted for 27% of 
the interpopulation differences in Lp(a) concentrations 
(Figure 5). It thus represents the largest contributor to the 
interpopulation differences without being, however, the only 
causal factor. This is in line with previous reports showing 
that differences in isoform distribution among populations 
only partially account for interpopulation differences in 
Lp(a) concentrations.1,5
We found that in YFS, the Lp(a) concentrations were 
reduced even within the same-isoform group. This mirrors 
the differences between blacks and whites, where blacks 
present higher Lp(a) concentrations over the whole range of 
isoforms.17,50The effect was most striking in the 11 to 16 KIV 
repeats group, which showed even lower Lp(a) than the 17 
to 19 KIV repeats group (Figures 3B and 4). Finns have a 
higher frequency of LOF mutations and variants in conserved 
noncoding regions than Central Europeans.6,51 Because LPA 
is reported to be LOF tolerant by ExAC (according to the 
pLI/pRec scores on the ExAC website31) and by phenome-
wide studies,30 and it has been shown that Lp(a)-modifying 
SNPs can cluster with particular isoforms3,52; it is tempting to 
speculate that novel functional variants may exist in the 11 to 
16 KIV repeat carriers in YFS. Indeed, especially short iso-
forms according to the Western blot might represent truncated 
protein forms caused by novel nonsense or splice-site vari-
ants. Such truncated forms have been observed previously in 
Tyroleans with low Lp(a).8
Figure 3. Lp(a) (lipoprotein(a)) concentrations stratified by apo(a) 
(apolipoprotein(a)) isoform size. A, Median Lp(a) concentration 
stratified by low-molecular-weight (LMW)/high-molecular-weight 
(HMW) classification. In both groups, YFS (Cardiovascular Risk in 
Young Finns Study) presents lower median Lp(a) concentrations 
than Non-Finnish Central Europeans (NFE). The nonclustered 
populations are shown in Figure V in the online-only Data Supple-
ment. B, Median Lp(a) concentrations stratified by isoform size 
in groups of 3 to 5 KIV (kringle IV) isoforms (based on isoform 
1). YFS individuals express lower Lp(a) concentrations than 
NFE individuals in all isoform groups. In the group 11 to 16 KIV 
repeats, Finns have an even lower Lp(a) concentration than in the 
larger 17 to 19 KIV repeats group. Stratified number of carriers 
for each population and median Lp(a) concentrations are given in 
Tables IV and V in the online-only Data Supplement and Figure VI 
in the online-only Data Supplement.
Figure 4. Nonlinear spline, showing the effect of isoform 1 (ie, 
in heterozygotes, the smaller allele present) on untransformed 
Lp(a) (lipoprotein(a)) concentrations. The splines are centered at 
0 at isoform 1=27 (median on the Non-Finnish Central Europeans 
studies). The splines are derived from the multiple regression 
model additionally adjusting for the variables age, sex, estimated 
glomerular filtration rate, rs143411368, rs41272114, rs11591147, 
APOE2, and APOE4-carriers (Table V in the online-only Data 
Supplement). The spline for inverse-transformed Lp(a) is shown 
in Figure VIII in the online-only Data Supplement. YFS, Cardio-
vascular Risk in Young Finns Study; KORA, Cooperative Health 
Research in the Region of Augsburg, Kooperative Gesundheits-
forschung in der Region Augsburg; KIV, kringle IV.
1238  Arterioscler Thromb Vasc Biol  May 2018
Several studies proposed that (even frequent) SNPs contrib-
ute to interethnic differences in Lp(a) levels.53,54 The APOE iso-
forms vary between Finns and Central Europeans, with APOE2 
being rarer and APOE4 being more frequent in Finns. Although 
the individual impact of these genetic variants on Lp(a) has 
been described previously,6,7,9,10,12 their cumulative contribution 
in establishing low Lp(a) levels in Finns has not been evaluated 
to date. We showed that the frequency distribution of 2 LPA 
LOF variants and rs10455872 contributed for a total of ≈10% 
to the population difference. Conversely, APOE2 counteracts 
this by increasing Lp(a) and so contributes to closing the gap 
between the populations (Figure 5; Table VI in the online-only 
Data Supplement). Among the APOE genotypes, only APOE2 
showed an appreciable contribution in the mediation analy-
sis in this sample set, which is in line with previous results10 
(Figure 5; Table VI in the online-only Data Supplement). Of 
note, rs41272114—a major contributor in our mediation anal-
ysis—has been proposed also as a cause for the Lp(a) differ-
ences between whites and Africans.54 No effect of rs11591147 
was found, which is likely because of its small absolute effects 
on Lp(a) concentrations (1 mg/dL).13 We could also not con-
firm the high MAF (17.9%) of rs11591147 reported in Finns by 
ExAC (Table 1), but we rather support the MAF determined in 
the SISu (Sequencing Initiative in Suomi) project (4.2%).6
Importantly, the focus of the work at hands was to show 
that the observed differences in Lp(a) are not just because of 
a shifted isoform distribution and evaluate the contribution of 
known functional factors affecting Lp(a) concentrations. This 
left ≈28% of variance unexplained and suggests the existence 
of additional functional variation. Various types of genetic 
variants may contribute to this observation. The KIV-2 region 
plays a special role because it encompasses a considerable 
part of the LPA gene but is currently not captured by common 
genetic data set. However, also differences in the effect mag-
nitude or frequency of known variation outside the KIV-2 may 
play role. Comparative ultradeep sequencing studies and a 
Table 2. Results From Multiple Regression Analyses in the YFS and in NFE Combined (Using a Random Effects Model)
Variables
Frequencies/Mean 
Values in YFS Compared 
With NFE
Results From Multiple Regression Model on Lp(a)* Expected Consequence of the 
Differences in Variable Distribution 
on Lp(a) Levels in YFS Compared 
With NFE
YFS NFE (Mixed Model)
β P Value β P Value
Age ↓ 0.07 0.3962 0.13 8.19×10−11 ↓
Sex (F) ↔ 0.62 0.0368 2.77 4.84×10−20 ↔
Isoforms† ↑ NA 2.60×10−124 NA <1×10−300 ↓
eGFR ↑ −0.03 0.1899 −0.03 0.0053 ↓
rs143411368‡ ↑ −2.6 5.33×10−9 −3.22 0.0334 ↓
rs41272114‡ ↑ −2.45 6.38×10−19 −6.05 7.67×10−58 ↓
rs11591147‡ ↑ 0.53 0.9545 −0.58 0.3769 ↔
rs10455872‡ ↓ 11.68 1.33×10−13 18.69 1.50×10−74 ↓
rs3798220 ↔ 28.03 3.37×10−14 43.54 1.35×10−89 ↔
APOE2 ↓ −2.34 0.0071 −3.60 1.60×10−16 ↑
APOE4 ↑ −0.21 0.6147 −0.34 0.23 570 ↔
eGFR indicates estimated glomerular filtration rate; Lp(a), lipoprotein(a); NFE, Non-Finnish Central Europeans; and YFS, Cardiovascular Risk in Young Finns Study.
*β estimate is derived from model on Lp(a). P value is derived from model on inverse-normal transformed Lp(a) values to ensure normal distribution assumption.
†P values for isoforms refer to the significance of a nonlinear spline of isoform 1 on inverse-normal transformed Lp(a); for effect size, see nonlinear spline in Figure 5.
‡For SNPs (single nucleotide polymorphisms), an additive inheritance model was assumed.
NA, effect is given as spline in Figure 4.
Figure 5. Mediation analysis explaining the differences in Lp(a) 
(lipoprotein(a)) concentrations between YFS (Cardiovascular 
Risk in Young Finns Study) and Non-Finnish Central Europeans: 
decomposition of the total effect on inverse-normal transformed 
Lp(a) values into explained and unexplained relative effects 
(including 95% confidence interval). Exact values are reported in 
Table VII in the online-only Data Supplement. eGFR, estimated 
glomerular filtration rate; apo(a), apolipoprotein(a).
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dedicated study design will be required to pinpoint the genetic 
determinants of the population differences reported here.
Strengths and Limitations
Our study presents strengths and limitations. To the best of 
our knowledge, here we present the largest investigation of 
Lp(a) concentrations in European populations accounting for 
Lp(a) isoform data to date. All measurements and Western 
blots were done in a single laboratory using the same meth-
ods in all populations. The YFS individuals are younger and 
present better renal function—a major determinant of Lp(a) 
levels1—than the NFE. Accordingly, environmental differ-
ences account for 34% of the population differences, and age 
and eGFR were the second largest contributors to the popula-
tion differences. This underscores the importance of match-
ing these factors, despite the often alleged robustness Lp(a) to 
nongenetic influences.
The pronounced effect of age is surprising and could 
reflect kidney function parameters, which are not reflected 
by eGFR, other unmeasured age-related confounders (eg, 
hormonal status), or undetermined study-specific confound-
ers, which are specific for the YFS study. The difference 
between YFS and NFE is present in both sexes (Table I in 
the online-only Data Supplement) and also when looking 
only at the age range ≥32 to ≤39, where all studies overlap. 
This indicates that the observed Lp(a) reduction is not only 
because of different proportion of postmenopausal individu-
als in NFE. Finally, it has to be noted that the mediation 
analysis assumes a linear and homogeneous effect of the fac-
tors. Therefore, the differing effect of low isoforms on Lp(a) 
in YFS cannot be fully accounted for and may contribute to 
the unexplained effect.
Importantly, no other study with combined information 
on Lp(a) concentrations and isoform distribution in Finns 
was available until now, except 1 small study in 181 indi-
viduals.27 We could successfully identify and quantify deter-
minants of the Lp(a) differences between Finns and NFE and 
show that a limited number of genetic elements (isoforms 
and SNPs) already explain remarkable ≈37% of the popula-
tion difference. This may indicate that a small number of 
factors can already explain a consistent part of differences of 
Lp(a) between Finns and NFE populations. Finally, the avail-
ability of Western blot data allowed identifying a surprising 
Lp(a)-lowering effect in short isoforms in YFS, which war-
rants further research.
Conclusion
We demonstrate that the lower Lp(a) concentrations in 
Finns are not caused solely by differences in isoform distri-
bution but are lowered across the whole range of isoforms. 
Frequency differences of common LOF mutations and 
APOE isoforms significantly contribute to these findings but 
do not fully explain it. Of particular note, especially very 
small isoforms with 11 to 16 KIV repeats present massively 
lowered Lp(a) concentrations, which might hint toward 
the existence of novel LOF mutations. Therefore, future 
sequencing studies in LPA might be fruitful to identify novel 
Lp(a)-lowering variants.
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Highlights
• Lp(a) (lipoprotein(a)) concentrations are massively reduced by ≈50% in Finns (n=2281) compared with Central Europeans (n=10 003).
• Finns presented a shift in apo(a) isoform distribution toward larger isoforms and frequency differences in established Lp(a)-regulating genetic 
variants (LPA loss-of-functions, APOE, and PCSK9).
• Lp(a) was reduced over the whole isoform range. Of particular note, very small isoforms showed surprisingly low Lp(a) concentrations.
• 71.8% of the differences between the populations can be explained by a combination of genetic and environmental factors.
